Loading...
•
Dec 31, 2025
Penumbra Q4 2025 Earnings Report
Penumbra reported strong Q4 2025 results with double-digit revenue growth and expanding margins.
Key Takeaways
In Q4 2025, Penumbra generated revenue of 385385000 and net income of 47343000, reflecting 22.1% year-over-year growth, margin expansion, and strong performance across thrombectomy and embolization and access products.
Revenue increased 22.1% year-over-year to 385385000.
Gross margin expanded to 68.0% from 66.8% in Q4 2024.
Net income rose to 47343000 with margin of 12.3%.
Embolization and access revenue grew 37.0% year-over-year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company will not provide full year 2026 guidance due to the proposed acquisition by Boston Scientific.
Positive Outlook
- Strong double-digit revenue growth.
- Margin expansion across gross and EBITDA levels.
- Operating income increased year-over-year.
- Strong U.S. and international growth.
- Improved profitability compared to prior year.
Challenges Ahead
- No 2026 financial guidance provided.
- Pending acquisition introduces uncertainty.
- Operating expenses increased year-over-year.
- Exposure to foreign currency fluctuations.
- Reliance on continued product mix improvement.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...